(ABC News/WRTV) — Two officials familiar with the matter tell ABC News the FDA could authorize second booster shots for Americans over 50 years old as soon as Tuesday.
The officials stressed that the details are still under discussion and could change in the next few days.
If the FDA authorizes it, the Centers for Disease Control and Prevention (CDC) will then give guidance on how to implement it in pharmacies and doctors offices nationwide.
ABC News reports the language from CDC Director Rochelle Walensky is expected to be that people over 50 may get a second booster shot, rather than should get a second booster shot.
RELATED: Moderna: Trials for COVID-19 vaccine for kids aged 6 months to 5 years shows shot is effective
FDA's panel of experts will convene on April 6 to discuss the broader population and what population will need booster shots next, as well as the need for a variant-specific booster.
Officials weighing the decision are also considering that anyone who gets a booster this spring would likely get boosted again when they are recommended for the broader public later this year, potentially in the fall, according to another person familiar with the matter.
-
Senator wants change following WRTV Investigation into mental health facilities
A state senator is pushing for sweeping change following a WRTV Investigation into a Lawrence mental health facility.
Hoosiers raise awareness about men's health issues for 'Movember'
You may notice many mustachioed men around Central Indiana this November. Some are adorning facial hair to raise awareness of prostate cancer, testicular cancer, mental health and suicide.
Pacers end 3-game skid, extend Wizards losing streak to 11 with 115-103 victory
After not playing well defensively for the past three games, Sunday's game showed modest improvement as Indiana allowed just 16 fourth-quarter points.
Richardson's rocky start proves costly in 2nd straight home loss
Anthony Richardson showed the Indianapolis Colts a little bit of everything Sunday. He provided some promising glimpses but also unnecessary risks and inconsistencies.
